Welcome to our dedicated page for Cemtrex SEC filings (Ticker: CETX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cemtrex, Inc. (CETX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cemtrex is a diversified industrial and technology company with Security, Industrial, and Aerospace & Defense segments, and its filings offer detailed information on capital structure, acquisitions, and corporate actions that affect CETX shareholders.
Among the key documents are Form 8-K current reports, where Cemtrex discloses material events. Recent 8-K filings describe a 1-for-15 reverse stock split approved by the board to address Nasdaq listing requirements, a promissory note with Streeterville Capital, LLC used to fund potential acquisitions, and a share purchase agreement to acquire Invocon, Inc., a systems-engineering firm in aerospace and defense. Another 8-K details a securities purchase agreement for a registered direct offering of common stock and pre-funded warrants, including gross proceeds and closing terms.
Investors can also review filings related to equity and preferred stock, such as disclosures on Series 1 Preferred Stock dividends paid in additional preferred shares, and unregistered sales of equity securities. These documents explain dividend terms, preference amounts, and how preferred stock fits into Cemtrex’s capital structure.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand items such as reverse stock split mechanics, acquisition agreements, and financing terms. Real-time updates from the SEC’s EDGAR system ensure that new CETX filings, including future 10-K annual reports, 10-Q quarterly reports, and Form 4 insider transaction reports when available, are added promptly.
By using this page, investors can study Cemtrex’s official disclosures on acquisitions, financing arrangements, stock splits, and preferred stock dividends, while AI-generated insights help clarify complex legal and financial language.
Cemtrex, Inc. entered a material definitive agreement, issuing a promissory note to Streeterville Capital, LLC with an original principal of $7,025,000. After $25,000 in original issuance fees, the company received $7,000,000 in cash.
Interest accrues at the daily SOFR rate from November 7, 2025 through December 31, 2025, then at 8% per annum beginning January 1, 2026. If the note remains outstanding on January 1, 2026, a one-time additional interest fee of $1,050,000 will be added to the balance. The note matures eighteen months from issuance, with redemptions starting six months after issuance. Cemtrex states it intends to use the cash proceeds to complete potential acquisitions.
Cemtrex Inc. is implementing a 1-for-15 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 29, 2025. The stock will begin trading on a split-adjusted basis that day under the same trading symbol, CETX, with a new CUSIP number 15130G873.
As of this filing, Cemtrex has 11,084,809 shares of common stock outstanding, which will be reduced to roughly one-fifteenth of that amount after the split, subject to rounding of fractional shares. The reverse split was approved earlier by stockholders and is intended to help the company regain compliance with Nasdaq’s minimum $1.00 bid price requirement.
Most options, warrants, and equity awards will be proportionately adjusted so that holders keep essentially the same aggregate exercise price. However, Cemtrex discloses that its Adjustable Warrants, currently exercisable for 15,412,956 shares at an exercise price of $0.5737 per share, contain provisions that will reduce the post-split exercise price and significantly increase the number of underlying shares, while keeping the total exercise price the same.
Cemtrex Inc. reported that its board of directors approved payment of the upcoming dividend on its Series 1 Preferred Stock in additional shares of the same Series 1 Preferred Stock rather than in cash. The new shares are expected to be issued on October 7, 2025 to holders of record as of the close of business on September 30, 2025.
Holders of the Series 1 Preferred Stock are entitled to receive dividends at a 10% annual rate, based on a $10.00 per share preference amount, with dividends payable on a semiannual schedule.
CEMTREX Inc. is the subject of a jointly filed Schedule 13G/A by three Altium-related reporting persons that discloses no reportable stake in the company’s common stock. The filing names Altium Healthcare Long Short Onshore Fund LP, Altium Capital Management LLC and Altium Healthcare Long Short GP LLC and states the Fund as the record and direct beneficial owner of the securities covered by the statement while simultaneously reporting an aggregate beneficial ownership of 0 shares (0% of the class). The filers note they may be deemed members of a group for regulatory purposes but expressly state the filing is not an admission of beneficial ownership or of acting to acquire or influence control. The statement also includes a certification that the securities were not acquired to influence control.
This Schedule 13G/A discloses that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the Reporting Persons) are each deemed to beneficially own 336,801 shares of Cemtrex Inc. common stock, representing approximately 9.99% of the company’s outstanding common stock as presented in the filing. The shares reported are issuable upon exercise of a warrant held by Intracoastal (Intracoastal Warrant 1).
Each Reporting Person has shared voting and shared dispositive power over 336,801 shares and no sole voting or dispositive power. The filing explains that blocker provisions in Intracoastal Warrant 1 and Intracoastal Warrant 2 prevent exercise to the extent doing so would increase ownership above 9.99% and 4.99%, respectively, thereby excluding 1,671,598 and 142,778 warrant shares from current beneficial ownership calculations. Without those blocker provisions, the Reporting Persons may be deemed to beneficially own 2,151,177 shares.